PeptideScouterPeptideScouterIndex

Mazdutide vs Retatrutide vs Survodutide: Differences

· Education

Mazdutide, retatrutide and survodutide all activate the glucagon receptor alongside the glucagon-like peptide-1 (GLP-1) receptor, the target of semaglutide. Mazdutide and survodutide stop at those two receptors, which makes them dual agonists. Retatrutide adds a third, the receptor for glucose-dependent insulinotropic polypeptide (GIP), which tirzepatide also activates.

The three sit at different regulatory stages. Mazdutide has been approved in China since June 2025. Retatrutide and survodutide are investigational, each with Phase 3 obesity results published in 2026. None of the three is approved by the U.S. Food and Drug Administration (FDA), and as of November 9, 2026, no trial registered on ClinicalTrials.gov compares any two of them directly.

How the three molecules differ

Each is a single peptide, and FDA's substance registry records the three structures:

The case for adding glucagon comes from oxyntomodulin, a gut hormone that activates both the glucagon and GLP-1 receptors. Boehringer's discovery paper for survodutide notes that oxyntomodulin reduces body weight in humans by raising energy expenditure as well as lowering energy intake. The same paper describes survodutide's fatty acid as a half-life extender.

Retatrutide's three activities are not equal. Lilly's discovery paper reports balanced glucagon-receptor and GLP-1-receptor activity in vitro and more GIP-receptor activity. In obese mice, it found that glucagon-receptor activity added an increase in energy expenditure to the reduced calorie intake driven by the other two receptors.

Mazdutide vs retatrutide

Both molecules carry Eli Lilly compound codes. They differ in receptor count and in where their evidence comes from.

Mazdutide's Phase 3 trials were funded by Innovent and enrolled Chinese adults:

GLORY-1's figures count participants whether or not they stayed on treatment. Outside China, a Lilly-funded Phase 2 trial in 179 U.S. adults (Lancet Diabetes & Endocrinology, 2026) tested higher doses and reported weight reductions of up to 18.1% at 32 weeks, against 0.9% with placebo, under an analysis that estimates the effect had participants stayed on treatment.

Retatrutide's Phase 3 trial in adults without diabetes is TRIUMPH-1, published in the New England Journal of Medicine in 2026. It randomized 2,339 adults with obesity or overweight for 80 weeks. Weight fell 25.0% in the highest-dose group, against 3.9% with placebo, counting participants whether or not they stayed on treatment.

Approval is where the two diverge most. Mazdutide was approved in China for long-term weight management in June 2025 and for glycemic control in type 2 diabetes in September 2025, and it is sold there as Xinermei. As of November 9, 2026, ClinicalTrials.gov lists Lilly-sponsored mazdutide trials through Phase 2 and none in Phase 3. Retatrutide is investigational, and Lilly said in September 2026 that it plans to submit a Biologics License Application (BLA) to FDA in the first quarter of 2027.

Survodutide vs retatrutide

Survodutide and retatrutide both have Phase 3 obesity results published in the New England Journal of Medicine in 2026.

SYNCHRONIZE-1, funded by Boehringer Ingelheim, enrolled 725 adults with obesity or overweight and without diabetes for 76 weeks. Weight fell 12.2% and 13.0% with the two doses, against 5.4% with placebo. Like TRIUMPH-1's 25.0%, those figures count participants whether or not they stayed on treatment.

The two trials still differ in length and in participants, and their placebo groups lost different amounts (5.4% and 3.9%). Separate trials cannot establish which compound would produce the larger effect in the same people, and retatrutide vs tirzepatide vs semaglutide explains why.

Survodutide's program is also aimed at the liver. In a Phase 2 trial of 293 adults with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, published in the New England Journal of Medicine in 2024, MASH improved without worsening of fibrosis in 43% to 62% of the survodutide groups at 48 weeks, against 14% with placebo. Two Phase 3 trials in MASH, LIVERAGE and LIVERAGE-Cirrhosis, are recruiting.

Survodutide vs mazdutide

Survodutide and mazdutide activate the same two receptors, and they are different molecules from different companies. Survodutide is the 29-amino-acid chain from Boehringer Ingelheim, and mazdutide is the 34-amino-acid chain from Eli Lilly and Innovent.

Their evidence was gathered differently too. Mazdutide's Phase 3 obesity trials enrolled Chinese adults and measured their primary endpoints at 32 and 60 weeks, while SYNCHRONIZE-1 measured its endpoint at 76 weeks. The participants also started from different places: mean BMI at baseline was 31.1 in GLORY-1 and 37.9 in SYNCHRONIZE-1.

Mazdutide is approved in one country. Survodutide remains investigational.

Reading the figures

A sponsor's announcement and the journal publication can give different numbers for one trial. Lilly's May 2026 announcement of TRIUMPH-1 led with 28.3%, an estimate of the effect had every participant stayed on treatment, and the published analysis that counts everyone gives 25.0%. Both describe the same trial.

In each of the obesity trials above, gastrointestinal events were the most common adverse events.

Approval status and research listings

Drugs@FDA, the agency's database of approved products, returns no application for mazdutide, retatrutide or survodutide as of November 9, 2026. Mazdutide's approval in China belongs to a specific product, Xinermei, and does not extend to research-grade material sold under the same compound name.

Research vendors mostly list mazdutide and survodutide under their own names. Retatrutide is more often sold under product codes such as GLP-3, and what GLP-3 means explains them.

What they cost

As of November 9, 2026, 46 of the 47 vendors in our index list retatrutide, 12 list survodutide and 8 list mazdutide. Median price per milligram for a single 10mg vial, the size most sellers of each compound carry, one price per vendor:

Each median covers a different set of vendors, so the three figures do not rank the compounds. Within single vendors the order changes:

Retatrutide is also sold in many more sizes, and larger vials cost less per milligram: a median of $5.25 per mg at 20mg across 35 vendors, $4.92 at 30mg across 42 and $3.63 at 60mg across 23. Multi-vial kits and non-vial formats are left out of these figures. Definitions are on the methodology page.

Sources

Prices are as of November 9, 2026, computed from PeptideScouter's own daily price archive. Sources checked November 9, 2026.

PeptideScouter indexes vendor prices for research chemicals sold for laboratory use only, not for human consumption. Nothing here is medical, legal, or investment advice. We earn affiliate commissions on some outbound vendor links - see our disclosure.